Dr. Hsieh on Unmet Needs of Rare Kidney Cancer Variants

Partner | Cancer Centers | <b>Siteman</b>

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

James J. Hsieh, MD, PhD, professor of medicine, Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses unmet needs in non-clear cell renal cell carcinoma (RCC).

Over the past 15 years, clear cell RCC has gained 15 novel treatments that target 7 different mechanisms, says Hsieh. These options have led to increased survival for these patients who make up the majority of kidney cancers.

However, little progress has been made in non-clear cell RCC, Hsieh says. Due to the rarity of non-clear cell RCC, it is difficult to enroll patients on clinical trials. As a result, little progress has been made in this group of patients with a relatively poor prognosis.

Hsieh hopes that clinical trials will expand to non-clear cell RCC, so the field can work toward better understanding the mechanisms of the disease and improving patient outcomes.